81 related articles for article (PubMed ID: 35243392)
1. Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer.
Fischer-Valuck BW; Baumann BC; Brown SA; Filson CP; Weiss A; Mueller R; Liu Y; Brenneman RJ; Sanda M; Michalski JM; Gay HA; James Rao Y; Pattaras JG; Jani AB; Hershatter B; Patel SA
Eur Urol Open Sci; 2022 Mar; 37():80-89. PubMed ID: 35243392
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Gomez-Veiga F; Szmulewitz RZ; Holzbeierlein J; Azad AA; Iguchi T; Villers A; Alcaraz A; Alekseev B; Shore ND; Rosbrook B; Zohren F; Ma J; Haas GP; Stenzl A; Armstrong AJ
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38072761
[TBL] [Abstract][Full Text] [Related]
3. Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study.
Pumpalova YS; Ramakrishnan A; May M; Pentz A; Minkowitz S; Doherty S; Singh E; Chen WC; Rebbeck TR; Neugut AI; Joffe M
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38158645
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163].
Sartor O; Karrison TG; Sandler HM; Gomella LG; Amin M; Purdy J; Michalski JM; Garzotto MG; Pervez N; Balogh AG; Rodrigues GB; Souhami L; Neil Reaume M; Williams SG; Hannan R; Jones CU; Horwitz EM; Rodgers JP; Feng FY; Rosenthal SA
Eur Urol; 2024 Jun; ():. PubMed ID: 38897867
[TBL] [Abstract][Full Text] [Related]
5. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.
Deek MP; Sutera P; Jing Y; Gao R; Rothman E; Day H; Chang D; Dirix P; Armstrong AJ; Campbell B; Campos FL; Berenguer M; Ramotar M; Conde-Moreno A; Berlin A; Bosetti DG; Corcoran N; Koontz B; Mercier C; Siva S; Pryor D; Ost P; Huynh MA; Kroeze S; Stish B; Kiess A; Trock B; Tran PT; Gillessen S; Sweeney C
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38570239
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED).
Sentana-Lledo D; Chu X; Jarrard DF; Carducci MA; DiPaola RS; Wagner LI; Cella D; Sweeney CJ; Morgans AK
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38688766
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
Mak KS; Scannell Bryan M; Dignam JJ; Shipley WU; Lin Y; Peters CA; Gore EM; Rosenthal SA; Zeitzer KL; D'Souza DP; Horwitz EM; Pisansky TM; Maier JM; Chafe SM; Robin TP; Roach M; Tran PT; Souhami L; Michalski JM; Hartford AC; Feng FY; Sandler HM; Efstathiou JA
Eur Urol Focus; 2024 Feb; ():. PubMed ID: 38307806
[TBL] [Abstract][Full Text] [Related]
8. Cryosurgery Versus Primary Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Primary Radiotherapy: A Propensity-Matched Survival Analysis.
Bauman G; Ding K; Chin J; Nair S; Iaboni A; Crook J; Klotz L; Dearnaley D; Horwitz E; O'Callaghan C
Cureus; 2020 May; 12(5):e7983. PubMed ID: 32391232
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Care of Node-Positive Prostate Cancer Patients Across the United States: A National Cancer Data Base Analysis.
Moon DH; Basak RS; Chen RC
Clin Genitourin Cancer; 2017 Aug; ():. PubMed ID: 28939472
[TBL] [Abstract][Full Text] [Related]
10. Androgen Deprivation Therapy in Patients with Prostate Cancer is Associated with the Risk of Subsequent Alzheimer's Disease but Not with Vascular Dementia.
Kim JW; Kim DK; Lee HS; Park JY; Ahn HK; Ha JS; Lee D; Cho KS
World J Mens Health; 2022 Jul; 40(3):481-489. PubMed ID: 34448373
[TBL] [Abstract][Full Text] [Related]
11. Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study.
Kim JH; Bae GH; Jung J; Noh TI
World J Mens Health; 2024 Mar; ():. PubMed ID: 38606859
[TBL] [Abstract][Full Text] [Related]
12. Variation in Androgen Deprivation Therapy Use Among Men With Intermediate-Risk Prostate Cancer: Results From a Statewide Radiation Oncology Quality Consortium.
Dykstra MP; Regan SN; Yin HM; McLaughlin PW; Boike T; Bhatt A; Zaki M; Kendrick D; Mislmani M; Paluch S; Litzenberg DW; Mietzel MA; Narayana V; Smith A; Heimburger DK; Schipper MJ; Jackson WC; Dess RT;
Int J Radiat Oncol Biol Phys; 2024 Jun; ():. PubMed ID: 38844140
[TBL] [Abstract][Full Text] [Related]
13. IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.
Ravi P; Wang V; Fichorova RN; McGregor B; Wei XX; Basaria S; Sweeney CJ
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37671811
[TBL] [Abstract][Full Text] [Related]
14. The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy.
Etheridge T; Liou J; Downs TM; Abel EJ; Richards KA; Jarrard DF
Am J Clin Exp Urol; 2018; 6(3):123-132. PubMed ID: 30038944
[TBL] [Abstract][Full Text] [Related]
15. Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana.
Meghani K; Puri P; Bazzett-Matabele L; Vuylsteke P; Luckett R; Monare B; Chiyapo S; Ketlametswe R; Ralefala TB; Bvochora-Nsingo M; Zetola N; Ramogola-Masire D; Grover S
Cancer; 2024 Mar; ():. PubMed ID: 38529676
[TBL] [Abstract][Full Text] [Related]
16. Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.
George DJ; Agarwal N; Ramaswamy K; Klaassen Z; Bitting RL; Russell D; Sandin R; Emir B; Yang H; Song W; Lin Y; Hong A; Gao W; Freedland SJ
Prostate Cancer Prostatic Dis; 2024 Apr; ():. PubMed ID: 38565911
[TBL] [Abstract][Full Text] [Related]
17. Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population-based cohort study.
Lee YHA; Chan JSK; Hui JMH; Tang P; Liu K; Dee EC; Ng K; Tse G; Ng CF
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38140773
[TBL] [Abstract][Full Text] [Related]
18. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer.
Lundberg F; Robinson D; Bratt O; Fallara G; Lambe M; Johansson ALV
Acta Oncol; 2024 Mar; 63():95-104. PubMed ID: 38505996
[TBL] [Abstract][Full Text] [Related]
19. Oncologic Outcomes of Testosterone Therapy for Men on Active Surveillance for Prostate Cancer: A Population-based Analysis.
Kaplan-Marans E; Zhang TR; Hu JC
Eur Urol Open Sci; 2024 Feb; 60():36-43. PubMed ID: 38375342
[TBL] [Abstract][Full Text] [Related]
20. Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry.
Benjamin DJ; Shrestha A; Fellman D; Cress RD; Lythgoe MP; Rezazadeh Kalebasty A
Prostate Cancer Prostatic Dis; 2023 Oct; ():. PubMed ID: 37798437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
